1. Home
  2. CGTX vs ZBAI Comparison

CGTX vs ZBAI Comparison

Compare CGTX & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTX
  • ZBAI
  • Stock Information
  • Founded
  • CGTX 2007
  • ZBAI 2015
  • Country
  • CGTX United States
  • ZBAI United States
  • Employees
  • CGTX N/A
  • ZBAI N/A
  • Industry
  • CGTX Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • CGTX Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • CGTX Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • CGTX 20.5M
  • ZBAI 17.3M
  • IPO Year
  • CGTX 2021
  • ZBAI N/A
  • Fundamental
  • Price
  • CGTX $0.41
  • ZBAI $0.34
  • Analyst Decision
  • CGTX Strong Buy
  • ZBAI
  • Analyst Count
  • CGTX 5
  • ZBAI 0
  • Target Price
  • CGTX $5.63
  • ZBAI N/A
  • AVG Volume (30 Days)
  • CGTX 2.0M
  • ZBAI 2.5M
  • Earning Date
  • CGTX 08-07-2025
  • ZBAI 06-06-2025
  • Dividend Yield
  • CGTX N/A
  • ZBAI N/A
  • EPS Growth
  • CGTX N/A
  • ZBAI N/A
  • EPS
  • CGTX N/A
  • ZBAI N/A
  • Revenue
  • CGTX N/A
  • ZBAI $720,000.00
  • Revenue This Year
  • CGTX N/A
  • ZBAI N/A
  • Revenue Next Year
  • CGTX N/A
  • ZBAI N/A
  • P/E Ratio
  • CGTX N/A
  • ZBAI N/A
  • Revenue Growth
  • CGTX N/A
  • ZBAI 44.00
  • 52 Week Low
  • CGTX $0.22
  • ZBAI $0.27
  • 52 Week High
  • CGTX $2.54
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • CGTX 67.18
  • ZBAI N/A
  • Support Level
  • CGTX $0.29
  • ZBAI N/A
  • Resistance Level
  • CGTX $0.34
  • ZBAI N/A
  • Average True Range (ATR)
  • CGTX 0.03
  • ZBAI 0.00
  • MACD
  • CGTX 0.01
  • ZBAI 0.00
  • Stochastic Oscillator
  • CGTX 92.43
  • ZBAI 0.00

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: